Fulcrum Therapeutics (FULC) Q3 2024 earnings summary

Executive summary

• Suspended losmapimod development after the Phase 3 REACH trial failed to meet endpoints, resulting in a 40% workforce reduction and a strategic shift to pociredir for sickle cell disease and early-stage programs in inherited aplastic anemias.

• Pociredir, an oral HbF inducer for SCD, is advancing in the Phase 1b PIONEER trial, with additional Phase 1 studies in healthy volunteers planned and FDA Fast Track and Orphan Drug Designation granted.

• Early-stage programs in inherited aplastic anemias (DBA, SDS, Fanconi anemia) are progressing under a CAMP4 licensing agreement, with updates on development candidate and IND-enabling studies expected.

• Management changes include Rachel King joining the board, Dr. Thomas Winkler leading hematology clinical development, and CMO Pat Horn retiring at year-end.

• Fulcrum reported $6.8 million net income for the nine months ended September 30, 2024, primarily due to an $80 million upfront payment from Sanofi for the losmapimod license outside the US.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $257.2 million as of September 30, 2024, up from $236.2 million at year-end 2023, mainly due to the $80 million Sanofi payment.

• Collaboration revenue rose to $80 million for the nine months ended September 30, 2024, driven by the Sanofi upfront payment; no collaboration revenue in Q3 2024 versus $0.8 million in Q3 2023.

• R&D expenses were $14.6 million in Q3 2024, down from $18.2 million in Q3 2023, reflecting Sanofi cost-sharing and lower losmapimod costs.

• General administrative expenses fell to $8.4 million in Q3 2024 from $10 million in Q3 2023, mainly due to workforce reduction.

• Net loss was $21.7 million in Q3 2024, compared to $24 million in Q3 2023; net income for the nine months ended September 30, 2024, was $6.8 million.

Outlook and guidance

• Cash runway is projected into at least 2027, with year-end 2024 cash expected to be approximately $240 million and 2025 cash burn forecasted at $55–$65 million.

• Clinical data from the ongoing Phase 1b PIONEER trial of pociredir in SCD is expected in 2025, with more detailed guidance to be provided early in the year.

• Plans to discuss expansion of the pociredir patient population with the FDA after current cohort data.

• No further revenue is expected from the Sanofi collaboration due to the suspension of losmapimod development.